151 related articles for article (PubMed ID: 35868517)
1. Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington's Disease Brain.
Petry S; Nateghi B; Keraudren R; Sergeant N; Planel E; Hébert SS; St-Amour I
Neuroscience; 2023 May; 518():54-63. PubMed ID: 35868517
[TBL] [Abstract][Full Text] [Related]
2. Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.
St-Amour I; Turgeon A; Goupil C; Planel E; Hébert SS
Acta Neuropathol; 2018 Feb; 135(2):249-265. PubMed ID: 29134321
[TBL] [Abstract][Full Text] [Related]
3. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD.
Bowles KR; Pugh DA; Oja LM; Jadow BM; Farrell K; Whitney K; Sharma A; Cherry JD; Raj T; Pereira AC; Crary JF; Goate AM
Acta Neuropathol; 2022 Feb; 143(2):225-243. PubMed ID: 34874463
[TBL] [Abstract][Full Text] [Related]
5. PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.
Ray P; Kar A; Fushimi K; Havlioglu N; Chen X; Wu JY
J Mol Neurosci; 2011 Nov; 45(3):453-66. PubMed ID: 21881826
[TBL] [Abstract][Full Text] [Related]
6. The role of tau in the pathological process and clinical expression of Huntington's disease.
Vuono R; Winder-Rhodes S; de Silva R; Cisbani G; Drouin-Ouellet J; ; Spillantini MG; Cicchetti F; Barker RA
Brain; 2015 Jul; 138(Pt 7):1907-18. PubMed ID: 25953777
[TBL] [Abstract][Full Text] [Related]
7. Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.
Mees I; Nisbet RM; Hannan AJ; Renoir T
J Huntingtons Dis; 2023; 12(1):1-13. PubMed ID: 37092231
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.
Espíndola SL; Damianich A; Alvarez RJ; Sartor M; Belforte JE; Ferrario JE; Gallo JM; Avale ME
Cell Rep; 2018 Apr; 23(3):709-715. PubMed ID: 29669277
[TBL] [Abstract][Full Text] [Related]
9. MAP2 Splicing is Altered in Huntington's Disease.
Cabrera JR; Lucas JJ
Brain Pathol; 2017 Mar; 27(2):181-189. PubMed ID: 27098187
[TBL] [Abstract][Full Text] [Related]
10. An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.
Krach F; Stemick J; Boerstler T; Weiss A; Lingos I; Reischl S; Meixner H; Ploetz S; Farrell M; Hehr U; Kohl Z; Winner B; Winkler J
Nat Commun; 2022 Nov; 13(1):6797. PubMed ID: 36357392
[TBL] [Abstract][Full Text] [Related]
11. Tau and saitohin gene expression pattern in progressive supranuclear palsy.
Ezquerra M; Gaig C; Ascaso C; Muñoz E; Tolosa E
Brain Res; 2007 May; 1145():168-76. PubMed ID: 17320831
[TBL] [Abstract][Full Text] [Related]
12. Regulation of alternative splicing of tau exon 10.
Qian W; Liu F
Neurosci Bull; 2014 Apr; 30(2):367-77. PubMed ID: 24627328
[TBL] [Abstract][Full Text] [Related]
13. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.
Gu J; Chen F; Iqbal K; Gong CX; Wang X; Liu F
J Biol Chem; 2017 Jun; 292(25):10600-10612. PubMed ID: 28487370
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy.
Smith PY; Delay C; Girard J; Papon MA; Planel E; Sergeant N; Buée L; Hébert SS
Hum Mol Genet; 2011 Oct; 20(20):4016-24. PubMed ID: 21807765
[TBL] [Abstract][Full Text] [Related]
15. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease.
Glatz DC; Rujescu D; Tang Y; Berendt FJ; Hartmann AM; Faltraco F; Rosenberg C; Hulette C; Jellinger K; Hampel H; Riederer P; Möller HJ; Andreadis A; Henkel K; Stamm S
J Neurochem; 2006 Feb; 96(3):635-44. PubMed ID: 16371011
[TBL] [Abstract][Full Text] [Related]
16. Huntington's disease is a four-repeat tauopathy with tau nuclear rods.
Fernández-Nogales M; Cabrera JR; Santos-Galindo M; Hoozemans JJ; Ferrer I; Rozemuller AJ; Hernández F; Avila J; Lucas JJ
Nat Med; 2014 Aug; 20(8):881-5. PubMed ID: 25038828
[TBL] [Abstract][Full Text] [Related]
17. Huntingtin Exists as Multiple Splice Forms in Human Brain.
Mort M; Carlisle FA; Waite AJ; Elliston L; Allen ND; Jones L; Hughes AC
J Huntingtons Dis; 2015; 4(2):161-71. PubMed ID: 26397897
[TBL] [Abstract][Full Text] [Related]
18. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease.
Boutajangout A; Boom A; Leroy K; Brion JP
FEBS Lett; 2004 Oct; 576(1-2):183-9. PubMed ID: 15474035
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of Kidins220 isoforms in Huntington's disease.
Sebastián-Serrano Á; Simón-García A; Belmonte-Alfaro A; Pose-Utrilla J; Santos-Galindo M; Del Puerto A; García-Guerra L; Hernández IH; Schiavo G; Campanero MR; Lucas JJ; Iglesias T
Brain Pathol; 2020 Jan; 30(1):120-136. PubMed ID: 31264746
[TBL] [Abstract][Full Text] [Related]
20. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients.
Liu P; Smith BR; Huang ES; Mahesh A; Vonsattel JPG; Petersen AJ; Gomez-Pastor R; Ashe KH
Acta Neuropathol Commun; 2019 Jul; 7(1):111. PubMed ID: 31358058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
